Original Research Article

A study on steroids and immunosuppressants as risk factors for infections in SLE patients

V Shiney John1,*, N Rathnapriya2, S Vasanthi3

1 Dept. of Microbiology, Annai Arul Hospital, Chennai, Tamil Nadu, India
2 Dept. of Microbiology, Chengalpattu Medical College, Tamil Nadu, India
3 Dept. of Microbiology, Institute of Microbiology, Madras Medical College, Tamil Nadu, India

A R T I C L E  I N F O

Article history:
Received 17-08-2019
Accepted 04-09-2019
Available online 21-11-2019

Keywords:
SLE
Steroids
Cyclophosphamide
Immunosuppressants
Infections

A B S T R A C T

Introduction: Systemic lupus Erythematosus (SLE) patients are inherently at risk for infections. Steroids and other immunosuppressants used for treating SLE patients further increase the chances of infections. This study was done to find the association of immunosuppressants with the risk of development of infections in patients with SLE.

Materials and Methods: Appropriate samples were collected from 110 SLE patients with various infections and processed in Microbiology laboratory. Treatment history was also collected from the patients and analysis was done on infections in these patients.

Results: Daily prednisolone dosage ≥20 mg was associated with increased risk of infection with p value of <0.05 and in patients receiving Cyclophosphamide with steroids also risk of infection was higher with p value <0.05 which is also statistically significant.

Conclusion: Since there is strong association between higher dose of steroids and Cyclophosphamide therapy with risk of infections in SLE patients, judicious use of these drugs is recommended.

© 2019 Published by Innovative Publication. This is an open access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by/4.0/)

1. Introduction

SLE is the prototype of a systemic autoimmune disorder in which there is production of autoantibodies. SLE affects almost all organs of the body and it occurs mainly in women in their peak reproductive age. SLE may present with varying symptoms ranging from skin and joint involvement to those involving major organs. In a genetically predisposed individual infections play a key role in disease manifestation. The disease runs a course of flare-ups and remissions which may extent over a period of years or sometimes even decades.1

SLE is not a curable disease. Hence the treatment is aimed to control severe exacerbations and to develop maintenance strategies so as to suppress symptoms and prevent damage to organs. Nonsteroidal antiinflammatory drugs (NSAID), antimalarial (hydroxychloroquine), glucocorticoids and in severe cases immunosuppressants like Azathioprine, Mycophenolate mofetil (MMF), Methotrexate and Cyclophosphamide (CYC) are used for treating mild SLE without major organ involvement. Treatment of moderate to severe SLE consists of a period of induction therapy in which intensive immunosuppressive therapy is given which is followed by a longer period of maintenance therapy using less intensive immunosuppressants.

Corticosteroids are used either as single or as background therapy in combination with immunosuppressive agents at prednisolone doses ranging from 0.5 to 1.0 mg/kg/day in a single dose followed by gradual dosage tapering. When doses more than 0.6 mg/kg/day are used or in rapidly progressing severe disease bolus therapy of 1000 mg of methyl prednisolone i.v. daily for three days followed by 0.5 mg/kg/day of prednisolone is given.

Intermittent pulse CYC therapy (Intravenous route) is effective for moderate to severe proliferative nephritis.
The treatment is usually given in one of the three ways: 1) Once monthly IV for 6 months followed by two years of quarterly doses 2) CYC for 12 weeks followed by Azathioprine 3) CYC for 6 months fol lowed by Azathioprine or MMF. MMF is used to treat manifestations of SLE like proliferative nephritis, skin disease, refractory thrombocytopenia and pulmonary haemorrhage. Steroids predispose to infection by decreased inflammatory response and effector cell response in cell mediated immunity, lysis of lymphoid follicles and decreased immunoglobulin synthesis. Prolonged administration of steroids causes chronic changes in tissues such as skin atrophy which allow increased access of microorganisms into circulation further increasing risk of infection.

There is inherent risk for infections in SLE patients due to the presence of immunological dysfunctions. This susceptibility to develop infection is further enhanced by the immunosuppressive therapy. 30% to 50% of SLE patients develop infections during the course of their disease. The recognition and treatment of infections in this patient population are particularly difficult tasks because the clinical manifestations of infection may mimic those of the underlying disease, the effects of immunosuppressive therapy may decrease the usual manifestations of an infection such as fever and localizing signs of inflammation and the spectrum of pathogens is large making empiric treatment difficult. Diagnosing infections at an early stage is important as they may mimic SLE flares leading to a delay in diagnosis or inappropriate increase in doses of immunosuppressants with dreadful consequences.

There are not many published articles on relationship between daily dose of steroids and immunosuppressants with infections in SLE patients. Hence the present study was done to find the association of immunosuppressants with occurrence of infections in patients with SLE.

2. Materials and Methods

A total of 110 SLE patients with clinically suspected infections were included in this study. Clinical history, demographic information and treatment history were collected using specially designed questionnaire. Appropriate samples were collected from the patients under strict aseptic precautions and transported to the laboratory without delay and processed.

The samples were inoculated on suitable bacterial and fungal culture media. After incubation overnight, bacterial and fungal pathogens were identified by standard techniques as recommended by CLSI (Clinical and Laboratory Standards Institute). Infections occurring in patients taking prednisolone dose <20 mg/day were compared with those in patients taking dosage of ≥20 mg/day. Also analysis was done on infectious complications in patients on CYC with steroids and also in SLE patients on MMF.

3. Results

From the 110 SLE patients the main samples collected were urine 84 (56%), sputum 22 (14.67%), and blood 21 (14%). 60 SLE patients included in the study had infectious episodes. Out of 150 samples processed, significant growth was observed in 74. Urinary tract infections 40 (54%) were common followed by respiratory tract infections 12 (16%). Other sites of infection in decreasing order of frequency were blood, skin & soft tissue, ear, oral cavity and peritoneum. Bacterial infections were common than fungal infections.

74 patients were on Prednisolone dose < 20 mg. Out of them infections were recorded in 31 (42%) patients. In this study 36 patients were on prednisolone dosage ≥ 20 mg and 29 (81%) of them presented with various types of infections. Daily prednisolone dosage ≥ 20 mg was associated with an increased risk of infection with a p value of 0.0003 (< 0.05 which is statistically significant).

Urinary tract infection (UTI) was the predominant infection and Escherichia coli was the common organism causing infection both in patients on steroids <20 mg/day and ≥20 mg/day.

29 patients were on treatment with CYC & Prednisolone, out of which 22 suffered from infections. In this group of patients Blood stream infections and UTI occurred in equal number and Pseudomonas aeruginosa was the predominant organism causing infections. In the remaining 81 patients who were not on CYC only 39 patients developed infections. Thus the risk of infections was higher in patients receiving both CYC & Prednisolone with a p value of 0.0183. (<0.05) which is statistically significant). Only 8 patients were on treatment with MMF and 4 of them developed infectious episodes. No association was found between MMF intake and infection with a p value of 0.7472. (>0.05 which is statistically not significant).

4. Discussion

In the present study out of 110 SLE patients 60 (55%) patients suffered from various infectious complications which is comparable to studies done by deluis et al and H – Al-Rayes et al. Urinary tract and respiratory tract were the most common sites of infection. (Tables 2, 3, 5 and 6) This finding is supported in other studies conducted by Ginzler e al, Staples P J et al and de Luis et al. In this study bacterial infections were common than fungal infections which is in agreement with studies conducted from India and other countries.

In the present study, daily prednisolone dose of ≥ 20 mg was associated with an increased risk of infection with a p value of < 0.05 which is statistically significant. (Table 1) Also in studies done by Noel et al and Gladman et al steroid intake was identified as a risk factor for infection in SLE patients. Ruiz- Irastorza et
Table 1: Steroid vs. infection (n = 110)

| Daily Prednisolone dosage | Total no. of patients | Infected | Not Infected |
|---------------------------|-----------------------|----------|--------------|
|                           | No.       | %     | No.         | %     |
| < 20 mg                   | 74        | 41.89%| 43          | 58.11%|
| ≥ 20 mg                   | 36        | 80.56%| 7           | 19.44%|
| Total                     | 110       | 60    | 50          |

Table 2: Infections in patients on prednisolone dose < 20 mg/day

| Infection site            | No of infections |
|---------------------------|------------------|
| Urinary tract             | 18               |
| Respiratory tract         | 4                |
| Skin & soft tissue        | 4                |
| Others                    | 5                |
| Total                     | 31               |

Organisms isolated from patients on prednisolone dose < 20 mg/day

| Organism                  | Number |
|----------------------------|--------|
| Escherichia coli           | 12     |
| Pseudomonas aeruginosa     | 6      |
| Klebsiella pneumoniae      | 5      |
| Candida albicans           | 3      |
| Staphylococcus epidermidis| 1      |
| Acinetobacter baumannii    | 1      |
| Proteus mirabilis          | 1      |
| Enterococcus faecalis      | 1      |
| Aspergillus flavus         | 1      |
| Total                      | 31     |

Table 3: Infections in patients on prednisolone dose ≥ 20 mg/day

| Infection site            | No of infections |
|----------------------------|------------------|
| Urinary tract             | 12               |
| Respiratory tract         | 8                |
| Blood                     | 6                |
| Others                    | 3                |
| Total                     | 29               |

Organisms isolated from patients on prednisolone dose ≥ 20 mg/day

| Organism                  | Number |
|----------------------------|--------|
| Escherichia coli           | 8      |
| Klebsiella pneumoniae      | 7      |
| Staphylococcus aureus      | 5      |
| Pseudomonas aeruginosa     | 4      |
| Staphylococcus epidermidis| 1      |
| Acinetobacter baumannii    | 1      |
| Salmonella typhi           | 1      |
| Enterococcus faecalis      | 1      |
| Candida tropicalis         | 1      |
| Total                      | 29     |

Table 4: Cyclophosphamide + steroid vs. Infection (n = 110)

|                  | Total no. of patients | Infected | Not Infected |
|------------------|-----------------------|----------|--------------|
|                  | No.       | %     | No.         | %     |
| No. of patients on Cyclophosphamide + Prednisolone | 29        | 22     | 75.86%  | 7     | 24.14%  |
| No. of patients not on Cyclophosphamide            | 81        | 39     | 48.15%  | 42    | 51.85%  |
| Total                                                | 110       | 61     | 51%      | 49    | 49%     |
Table 5: Infections in patients on cyclophosphamide+steroids

| Infection site         | No of infections |
|------------------------|------------------|
| Blood                  | 7                |
| Urinary tract          | 7                |
| Respiratory tract      | 4                |
| Others                 | 4                |
| **Total**              | **22**           |

Organisms isolated from patients on CYC+Steroids

| Organism                  | Number |
|---------------------------|--------|
| Pseudomonas aeruginosa    | 6      |
| Klebsiella pneumoniae     | 5      |
| Staphylococcus aureus     | 5      |
| Escherichia coli          | 4      |
| Acinetobacter baumannii   | 1      |
| Salmonella typhi          | 1      |
| **Total**                 | **22** |

Table 6: Infections in patients not on CYC

| Infection site         | No of infections |
|------------------------|------------------|
| Urinary tract          | 24               |
| Respiratory tract      | 7                |
| Skin & soft tissue     | 5                |
| Others                 | 3                |
| **Total**              | **39**           |

Organisms isolated from patients not on CYC

| Organism                  | Number |
|---------------------------|--------|
| Escherichia coli          | 10     |
| Pseudomonas aeruginosa    | 8      |
| Klebsiella pneumoniae     | 6      |
| Staphylococcus aureus     | 5      |
| Candida albicans          | 3      |
| Enterococcus faecalis     | 2      |
| Proteus mirabilis         | 2      |
| Citrobacter freundii      | 1      |
| Candida tropicalis        | 1      |
| Aspergillus flavus        | 1      |
| **Total**                 | **39** |

Table 7: MMF vs. infection ( n=110)

|                              | Total no. of patients | Infected | Not Infected |
|------------------------------|-----------------------|----------|--------------|
| No. of patients on Mycophenolatemofetil | 8                      | 4        | 4            |
| No. of patients not on Mycophenolatemofetil | 102                   | 57       | 45           |
| **Total**                     | **110**               | **61**   | **49**       |

al found that prednisolone dose increases risk of infection in patients with SLE. The present study is comparable to the findings from above mentioned studies.

In the current study, the risk of infection was higher in patients receiving CYC with a p value <0.05 which is statistically significant. (Table 4) Pryor et al reported a higher rate of infection in patients receiving CYC and steroids. The present study is in line with the above study. In this study, eight patients were on treatment with MMF out of which four developed infection. No significant association was found between infection and MMF with a p value more than 0.05. (Table 7) In the study by Hu et al. it was found that the frequency of infection in SLE patients treated with MMF was less compared with patients on CYC.

Disease activity along with prednisolone dose more than 10 mg/day, methyl prednisolone in high doses and CYC therapy are well documented causes of increased risk of infection. Long term steroid use in SLE patients
reason for this increased risk. It was found that patients treated with plasmapheresis and CYC had more chances of developing infections compared to patients treated with CYC alone. Recent clinical trials suggest infections are less frequent in patients treated with MMF as compared to CYC. In a retrospective analysis, infection rate was found to be higher among patients receiving CYC and higher doses of steroids compared to patients on MMF. In a study on SLE infection predictive index, CYC infusion was found to be a major risk factor for infection. The cytotoxic action of CYC on lymphocytes could be a reason for this increased risk. In a large multi center study on SLE patients, corticosteroids dose ≥ 10mg/day and immunosuppressants were associated with infection whereas antimalarial use was found to be protective. Complement deficiency, use of steroids and cytotoxic drugs were attributed to infections in Saudi patients with SLE. The immune response to microorganisms is very much suppressed in patients receiving CYC in combination with high dose steroids. CYC regimen causes reduction in WBC count. This increases risk of serious infection in SLE patients. A high index of suspicion is essential as the symptoms of SLE and infection are often similar. The helpful clues which help to diagnose infections are presence of the following like chills, leukocytosis, increased C Reactive Protein (CRP) levels and absence of SLE involving multiple systems. SLE patients are at high risk for developing infection. Hence all fevers must be evaluated in SLE patients because the most common causes of fever in them are infections and active lupus. Also the signs of inflammation in these patients may be altered by steroids and NSAIDs which are used for treating disease manifestations. Thus careful use of steroids and other immunosuppressive agents in SLE patients is recommended to limit infections.

5. Conclusion

Since there is strong association between increased dose of steroids and CYC with risk of developing infections in SLE patients judicious use of steroids and other immunosuppressants is recommended. Also it is very important to diagnose infections at an early stage as they may mimic SLE flares which may lead to a delay in diagnosis or inappropriate increase in doses of immunosuppressants with dreadful consequences.

6. Conflict of interest

None.

References

1. Wallace DJ, Hah BH. Dubois’ Lupus Erythematosus, 7th edition, Chapter 45, Infections in Systemic Lupus Erythematosus.
2. Firestein GS, Budd RC, Harris ED, McInnis IB, Ruddy S, Sergent JS. Kelley’s textbook of Rheumatology, 8th edition, Vol. II, Chapter 75, Clinical features and treatment of Systemic Lupus Erythematosus.
3. Clinical and Laboratory Standards for Antimicrobial Susceptibility Testing; Twenty first Informational Supplement M100 - S21 ; 2011.
4. Luis AD, Pigrau C, Palassita A. Infections in 96 cases of systemic lupus erythematosus. Med Clin (Basel). 1990;94:607–610.
5. Al-Rayes H, Al-Swailim R, Sobki S, Rizvi S, Tariq M, M. Systemic lupus erythematosus and infections: a retrospective study in Saudis. Lupus. 2007;16:755–763.
6. Ginzelr E, Diamond H, Kaplan D. Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. Arthritis Rheum. 1978;21:37–44.
7. Gerdin PJ, Gerdin DN, Decker JL. Incidence of infection in systemic lupus erythematosus. Arthritis Rheum. 1974;17:1–10.
8. Luu HM, Chng HH, Bols HL. Infections in systemic lupus erythematosus. Singapore Med J. 1993;34:406–408.
9. Malaviya C, AN. Infection-related morbidity in systemic lupus erythematosus: a clinico-epidemiological study from northern India. Rheumatol Int. 1996;16:1–3.
10. Noel V, Lortholary O, Casassus P. Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus. Ann Rheum Dis. 2001;60:1141–1145.
11. Gladman DD, Hussain F, Ibaez D, Urowitz MB. The nature and outcome of infection in systemic lupus erythematosus, vol. 11. Lupus ; 2002. p. 234–239.
12. Pryor BD, Bologna SG, Kahl LE. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum. 1996;39:1475–82.
13. Bosch X, Guilabert A, Pallares L, Cervera R, Ramos-Casals M, et al. Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus. 2006;15:584–589.
14. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther. 2009;11:109–109.
15. Hu W, Liu Z, Chen H. Mycophenolatamofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J (Engl). 2002;115:705–714.
16. Danza A, Ruiz-Iratzaor G. Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. Lupus. 2013;22(12):1286–94. Available from: 10.1177/0961203313493032.
17. Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 2000;43(8):1801–1809.
18. Banerjee S. Low incidence of opportunistic Infections in SLE Patients treated with Cyclophosphamide and Steroids in a Tertiary care setting. Med Res Arch. 2017;5(3).
19. Torres-Ruiz. The Systemic Lupus Erythematosus Infection Predictive Index (LIPPI): A Clinical-Immunological Tool to Predict Infections in Lupus Patients ; 2019. Available from: 10.3390/immunu.2018.03144.
20. Rua-Figueroa I, Lopez-Longo J, Galindo-Izquierdo M, Calvo-Alen J, Campo VD, et al. Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2017;47:38–45.
21. Suh CH, Jeong YS, Park HC. Risk factors for infection and role of CRP in Korean patients with SLE. Clin Exp Rheumatol. 2001;19:191–195.
Author biography

V Shiney John Microbiologist

N Rathnapriya Associate Professor

S Vasanthi Retd. Professor

Cite this article: Shiney John V, Rathnapriya N, Vasanthi S. A study on steroids and immunosuppressants as risk factors for infections in SLE patients. *Indian J Microbiol Res* 2019;6(4):317-322.